miR-124 regulates liver cancer stem cells expansion and sorafenib resistance
- 1 September 2020
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 394 (2) , 112162
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81300326, 81802318)
This publication has 31 references indexed in Scilit:
- PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patientsJournal of Hepatology, 2015
- Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapyAdvanced Drug Delivery Reviews, 2015
- miRNA and Methylation: A Multifaceted LiaisonChemBioChem, 2014
- Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathwayCarcinogenesis, 2014
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib TreatmentCancer Discovery, 2014
- HIP1–ALK, A Novel ALK Fusion Variant that Responds to CrizotinibJournal of Thoracic Oncology, 2014
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinomaHepatology, 2012
- Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic TherapyClinical Cancer Research, 2012
- Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancerMedical Oncology, 2011
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell FeaturesGastroenterology, 2009